The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
Abstract
Purpose: To test whether eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia (CLL) by alemtuzumab is associated with a prolongation of treatment-free and overall survival. Patients and Methods: Ninety-one previously treated patients with CLL (74 men and 17 women; median age, 58 years [range, 32 to 75 years]; 44 were refractory to purine analogs) received a median of 9 weeks of alemtuzumab treatment between 1996 and 2003. Regular bone marrow assessments by MRD flow cytometry were performed with the aim of eradicating detectable MRD (< 1 CLL cell in 10 5 normal cells). Results: Responses according to National Cancer Institute-sponsored working group response criteria were complete remission (CR) in 32 patients (36%), partial remission (PR) in 17 patients (19%), and no response (NR) in 42 patients (46%). Twenty-two (50%) of 44 purine analog-refractory patients responded to alemtuzumab. Detectable CLL was eradicated from the blood and marrow in 18 patients (20%). Median survival was significantly longer in MRD-negative patients compared with those achieving an MRD-positive CR, PR, or NR. Patients achieving an MRD-negative CR had a longer treatment-free survival than patients with MRD-positive CRs, PR, or NR: MRD-negative CRs, not reached; MRD-positive CRs, 20 months; PRs, 13 months; NR, 6 months (P < .0001). Overall survival for the 18 patients with MRD-negative remissions was 84% at 60 months. Eight (47%) of the MRD-negative patients converted to MRD positivity at a median of 28 months. Conclusion: MRD-negative remission in CLL is achievable with alemtuzumab, leading to an improved overall and treatment-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Self-citationOscier, D. G., Gardiner, A. C., Mould, S. J., Glide, S., Davis, Z. A., Ibbotson, R. E., Corcoran, M. M., Chapman, R. M., Thomas, P. W., Copplestone, J. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1177.h81602001177_1177_1184 · Cited by 522
Self-citationOsterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P. W., Hamblin, T. J., Staudt, L. M., & Oscier, D. G. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15260-9 · Cited by 448
Self-citationRai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 307
Ginaldi, L., Martinis, M. D., Matutes, E., et al. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00158-6 · Cited by 269
Cited by
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationOfatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Self-citationEichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.019 · Cited by 585
Self-citationAlemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 561
Self-citationRawstron, A. C., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J. L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404584 · Cited by 403
Self-citation
Metadata
- Authors
- Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., & Hillmen, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-01
- Volume
- 23
- Issue
- 13
- Pages
- 2971-2979
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111403010
- Cited by
- 419
- References
- 20
- FWCI
- 20.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. https://app.cochat.ai/papers/10.1200/jco.2005.04.021
- The paper
- Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., & Hillmen, P. (2005). Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.